UBS Group’s Guardant Health GH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$859K Buy
+9,300
New +$934K ﹤0.01% 5665
2025
Q3
Sell
-5,000
Closed -$260K 10527
2025
Q2
$260K Buy
+5,000
New +$223K ﹤0.01% 6541
2022
Q4
Sell
-40,000
Closed -$2.15M 10863
2022
Q3
$2.15M Buy
+40,000
New +$2.05M ﹤0.01% 3096

Other funds holding GH

UBS Group's GH Position: Q1 2026 in Review

UBS Group reduced its Guardant Health (GH) stake by 18% in Q1 2026, selling an estimated $30.6M and leaving 1,405,837 shares worth $130M. The position accounts for 0.02% of the portfolio, ranked #856.

UBS Group first reported a position in GH in Q4 2018 and has held it in 30 quarters since. The position peaked at $175M in Q4 2025. 482 funds tracked by Wall St. Rank hold GH as of Q1 2026.

  • UBS Group held 1,405,837 shares of Guardant Health worth $130M as of Q1 2026.
  • UBS Group sold 304,332 Guardant Health shares in Q1 2026, an estimated $30.6M.
  • Guardant Health made up 0.02% of UBS Group's portfolio in Q1 2026, its #856 holding.
  • UBS Group first reported a position in Guardant Health in Q4 2018 and has held it in 30 quarters since.
  • UBS Group's Guardant Health position peaked at $175M in Q4 2025.
  • 482 funds tracked by Wall St. Rank held Guardant Health as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.